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Introduction: In the treatment of secondary hyperparathyroidism of chronic kidney disease, calcimimetics - allosteric
modulators of the calcium-sensing receptor - inhibit glandular hyperplasia and significantly reduce circulating
parathyroid hormone levels. They have a major impact on the management of secondary hyperparathyroidism.
Case presentation: We present the clinical case of a 41-year-old Caucasian man undergoing chronic hemodialysis, who
had a parathyroidectomy to treat severe secondary hyperparathyroidism resistant to cinacalcet treatment. Preoperatively,
24 months after high-dose cinacalcet hydrochloride, we observed a persistently elevated intact parathyroid hormone
serum level, and detected clear parathyroid gland hyperplasia regression on ultrasound. We performed a three-gland
parathyroidectomy, which was assumed to be total, associated with a hemithyroidectomy. Our patient then entered a
hypoparathyroid state. A histopathological examination showed that the removed parathyroid glands were of small size,
with a total weight of 1g, associated with a multifocal small papillary thyroid cancer.
Conclusion: In the management of secondary hyperparathyroidism, cinacalcet hydrochloride effectively reduces total
parathyroid gland hyperplasia. However, a persisting elevated intact parathyroid hormone serum level may be observed,
demonstrating that reduced parathyroid hyperplastic tissue may still be associated with severe secondary
hyperparathyroidism. Even if calcimimetics are very effective in secondary hyperparathyroidism treatment, further studies
are necessary for a better understanding of their actions.Introduction
Secondary hyperparathyroidism (2HPT) of chronic kid-
ney disease has a negative effect on patient morbidity,
inducing a higher mortality rate, particularly due to
cardiovascular complications. In patients undergoing
hemodialysis (HD), the incidence of 2HPT increases
with dialysis ‘vintage’. Prior to the calcimimetic era, a
parathyroidectomy (PTx) was necessary in 15% of cases
after 10 years, rising to 38% after 20 years [1]. First mar-
keted in 2004, calcimimetics - allosteric modulators of the
calcium-sensing receptor - inhibit glandular hyperplasia
and significantly reduce circulating parathyroid hormone
(PTH) levels [2]. Before their introduction, standard* Correspondence: giovanni.conzo@unina2.it
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reproduction in any medium, provided the ormedical treatment, consisting of phosphate chelators
(calcium carbonate, sevelamer, lanthanum carbonate),
dialysis baths with various calcium concentrations, and
vitamin D and its analogues, was ineffective in many
patients. Calcimimetics have demonstrated a major impact
on 2HPT management. Nevertheless, nodular hyperplasia,
typically associated with more advanced 2HPT, is less
responsive to conservative treatment, presumably because
of the reduced expression of calcium-sensing receptors
(CaSR) and vitamin D receptors (VDR). Although cinacal-
cet hydrochloride effectively reduces intact parathyroid
hormone (iPTH) levels, and is also effective in patients
refractory to vitamin D therapy, the effect of cinacalcet
hydrochloride in marked glandular hyperplasia is still the
subject of active research [3]. We report the case of a
patient with 2HPT, documenting that cinacalcet hydro-
chloride is able to reduce gland size, but is not able in all
cases to reduce PTH secretion.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We observed a 41-year-old Caucasian male patient who
underwent, at the age of 10 years, resection of epilepto-
genic tubers for tuberous sclerosis. He was also treated
with anticonvulsants for postoperative secondary refrac-
tory epilepsy (last therapy: phenobarbital 200mg per day;
levetiracetam 1000mg per day; lamotrigine 150mg per
day; vigabatrin 1500mg per day). He had giant kidney
angiomyolipomas and polycystic kidney disease. At 35
years old, he was started on standard three-weekly
HD treatment required for end-stage renal disease. A
bilateral nephrectomy was then performed.
Our patient developed severe 2HPT, and was managed
by paricalcitol (ZemplarW, 5μg three times a week) and
sevelamer (RenvelaW, 7.2g per day). Subsequently, he
developed acute alcoholic pancreatitis, and during this
period his compliance to therapy was insufficient. In
addition, he was ineligible for transplantation because of his
severe comorbidities. His 2HPT became resistant to me-
dical treatment and was associated with an iPTH serum
level of 1123pg/mL (normal range 4.6 to 58.1pg/mL), serum
calcium of 7.3mg/dL (normal range 8.9 to 10.3mg/dL, value
corrected with serum albumin), serum phosphate (P) of
4.7mg/dL (normal range 2.4 to 4.1mg/dL) and 25-hydroxy
vitamin D of 15ng/mL (normal range 30 to 74ng/mL)
(Table 1). Cinacalcet hydrochloride (30mg per day) was
administered from January 2010, and the dose was titrated
upwards in the following period. In March 2011, his iPTH
level was 1367pg/mL, and a cinacalcet hydrochloride
dosage of 180mg per day was required. Our patient was
referred to surgery for 2HPT resistant to medical treat-
ment, associated with persistently elevated serum iPTH
levels and clinical symptoms - anemia resistant to
erythropoiesis-stimulating agent therapy, arthromyal-
gias, osteopenia and mood alterations. However, due to
several intervening complications (arteriovenous fistulaTable 1 Mean monthly measurements performed during
the year
2010 2011 2012
Parathyroid hormone (pg/mL) 1123 1367 848
Calcium (mg/dL) 7.3 7.9 7.5
Phosphate (mg/dL) 4.7 5.4 5.5
Alkaline phosphatase (U/L) 770 678 700
Hemoglobin (g/dL) 10.0 9.2 9.0
Cinacalcet dose (mg/day) 30 90 to 180 180
Paricalcitol (mg/week) 15 15 15
Sevelamer (mg/day) 4.8 7.2 7.2
Erythropoietin beta (UI) 3000×3 6000×2 6000×3
Of note, asymptomatic hypocalcaemia is present as well as anemia resistant to
erythropoietin administration, requiring the increase of the erythropoietin
dose (the patient was iron replete).closure, catheter infection), surgery was postponed and
performed in February 2012.
Preoperative instrumental work-up had consisted of
measurements of his iPTH, calcium, phosphate, alkaline
phosphatase, free tri-iodothyronine, free thyroxine,
thyroid-stimulating hormone and thyroglobulin serum
levels; high resolution neck ultrasound (US); ear, nose and
throat examination; and technetium-99m sestamibi scin-
tigraphy. The LIAISONW intact PTH Assay (DiaSorin
Inc., Stillwater, MN, USA), based on a chemiluminescence
immunoassay, was used for the quantitative determination
of iPTH. A cardiac evaluation included a 12-lead echocar-
diogram and epiaortic two-dimensional and color Doppler
transthoracic echocardiogram. US examination showed
two bilateral hypoechoic hyperplastic parathyroid glands,
of 2.8×1.5×1.5cm (right gland) and 2.3×1.3×1.4cm (left
gland). A technetium-99 sestamibi scintigraphy revealed
hyperactive uptake activity in the same areas. Twelve
months after initiating cinacalcet hydrochloride therapy, a
regression of the parathyroid gland hyperplasia was
detected by US (right gland: 2.2×1.0×0.9cm; left gland:
1.9×1.0×0.7cm).
After an extensive neck exploration, including compre-
hensive exploration of the thyrothymic ligament, bilateral
thymic tongues and the jugular-carotid axis to rule out the
presence of ectopic and supernumerary glands, only three
glands were removed. Extemporary histological exami-
nation confirmed the nature of these removed glands. We
performed a, presumed total, PTx, not associated with
autoimplantation. We also carried out a right loboisthmu-
sectomy associated with thyrothymic ligament resection to
look for an intrathyroidal parathyroid gland. Parathyroid
tissue was not cryopreserved for re-transplant.
Our patient’s iPTH serum level was 629pg/mL before
anesthesia induction, 45pg/mL 20 minutes after surgery,
and 4pg/mL 24 hours after surgery. Severe hypocalcemia
was observed postoperatively, which was, however, never
associated with hypocalcemic seizures. A pathological
examination showed three hyperplastic nodular parathy-
roid glands and a multifocal small papillary thyroid car-
cinoma. The macroscopic parathyroid gland features are
reported in Figure 1. Parathyroid tissue showed diffuse
hyperplasia of chief cells with minimal fat. A focally
nodular pattern was observed, while infarction, and
fibrous or cystic degeneration were not observed. In
order to assess the degree of apoptosis in the examined
parathyroid tissue, an immunohistochemical study with
the B-cell lymphoma-2 protein was performed, with
adequate controls, using a monoclonal antibody, clone
124-VentanaW (Ventana Medical Systems, Inc., Tucson,
AZ, USA). No B-cell lymphoma-2 positive-staining cells
were detected in any of the examined glands.
Our patient’s postoperative course was uneventful
and he was discharged on day 4. Hypoparathyroidism
Figure 1 Removed parathyroid glands. Left lower parathyroid
gland: 1.2×0.8×0.3cm, weight 0.5g; left upper parathyroid gland:
1.7×0.5×0.2cm, weight 0.3g; right upper parathyroid gland:
0.7×0.6×0.3cm, weight 0.2g.
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calcemia was recorded two weeks and one month after
surgery. Two months postoperatively, our patient had a
subarachnoid hemorrhage and was moved to our intensive
unit care in a comatose status. Fourteen days later, after
recovery to generally acceptable clinical conditions, our
patient was discharged.
Discussion
In 2HPT of chronic kidney disease, parathyroid gland
hyperplasia, especially in its nodular form, is associated
with reduced expression of CaSR and VDR, determining
medical therapy resistance. Before cinacalcet hydrochlo-
ride was introduced, calcitriol and other vitamin D analo-
gues, which also enhance calcium and phosphate serum
levels, were considered the cornerstone of medical the-
rapy. A glandular volume greater than 500mm3 and nodu-
lar hyperplasia, often observed in patients refractory to
vitamin D treatment, are still considered the main medical
treatment resistance factors. Subsequently, it has been
shown that cinacalcet hydrochloride effectively reduces
iPTH levels while maintaining calcium and phosphate
levels within the normal range [3]. Komaba [4] reported
calcium treatment efficacy, confirming a rapid decline in
serum PTH levels, by 50%, in patients affected by severe
2HPT associated with suspected nodular hyperplasia and
reduced expression of CaSR and VDR. Cinacalcet hydro-
chloride therapy has been shown to upregulate VDR and
CaSR expression, facilitating medical therapy outcomes.
Experiments carried out in animal models demonstrated
reduced vascular and extraosseous calcifications.
Cinacalcet hydrochloride effects on the parathyroid
gland may also result in cell hypertrophy reduction and
increased apoptosis, determining the decrease in iPTH
serum levels. Its use may also increase oxyphil to chiefcell ratios and cystic degeneration. According to litera-
ture data [4-6], a decrease in PTH serum level is consi-
dered the main effect of cinacalcet hydrochloride
therapy, whereas parathyroid gland hypertrophy reduc-
tion is not reported in all patients. On the contrary, in
the reported case, despite high-dose cinacalcet hydro-
chloride therapy (180mg/day), carried out for a signifi-
cant amount of time (over six months), a significant
reduction in glandular volume, associated with persisting
high iPTH serum level, was observed on US. Only after
PTx did a hypoparathyroid state with severe hypocalce-
mia follow. However, we have to consider that prolonged
therapy with anticonvulsants may cause vitamin D defi-
ciency and hypocalcaemia [7].
We can consider several reasons for the low calcium
levels observed in the face of high iPTH: a small amount
of VDR expression in the cells; low compliance to oral
calcium therapy; and drug interaction by anticonvul-
sants. In addition, other factors besides CaSR and VDR ac-
tivity influence PTH release and synthesis. In particular,
the latter is regulated by PTH and CaSR gene transcrip-
tion, and variations in the amounts of messenger ribo-
nucleic acid (mRNA)-encoding PTH-binding proteins,
which are important for mRNA stability, can occur. RNA-
binding proteins interact with sequence-specific elements,
adenine- and uridine-rich elements, regulating the rate at
which mRNAs are translated or degraded [8]. In addition,
fibroblast growth factor 23 (FGF-23), usually much
increased in patients on HD, has direct actions on the
parathyroid gland, where it suppresses PTH secretion [9].
A markedly decreased expression of FGF receptor 1 and
Klotho protein (a transmembrane protein required for
FGF-23 receptor activation) in a hyperplastic parathyroid
gland is present in patients on HD [10]. It is possible to
hypothesize that variations of one of these factors are at
play in explaining the reason that high PTH levels were
present in our patient in association with a reduction in
gland size.
Conclusions
Our data suggest that further studies are necessary for a
better understanding of the actions of cinacalcet hydro-
chloride that cause its pharmacological effects. In par-
ticular, after cinacalcet therapy, we observed an unusual
small gland volume compared with other reported cases
of 2HPT, while iPTH levels remained elevated. A few
considerations can be made: first, in patients with 2HPT
and persistently elevated iPTH serum levels after six
months of high-dosage cinacalcet hydrochloride, medical
resistance is present and surgical intervention should be
recommended, especially in young patients. Second,
regarding surgical treatment, a <10% intraoperative de-
crease of iPTH with respect to the baseline value, 20
minutes after PTx, may be considered predictive of total
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a better choice in patients on a waiting list for renal
transplantation, especially when only three parathyroid
glands are intraoperatively identified and removed [11].
In fact, it is well recognized that in only about 3% of
patients with 2HPT on HD will three glands be present
[1]. The third consideration is that, in cases of unrespon-
siveness to medical treatment for 2HPT, especially in
young patients on HD, a multidisciplinary, early, aggres-
sive treatment (early surgery or high-dose calcimimetics
therapy) must be recommended to avoid severe cardio-
vascular events and other complications related to
chronic kidney disease, and to ameliorate quality of life.
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